Please login to the form below

Not currently logged in
Email:
Password:

Elocta

This page shows the latest Elocta news and features for those working in and with pharma, biotech and healthcare.

Shire claims EU approval for haemophilia A drug Adynovi

Shire claims EU approval for haemophilia A drug Adynovi

Shire claims EU approval for haemophilia A drug Adynovi. The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share. ... It is jostling for market share with other long-acting Factor VIII products for haemophilia A,

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    The process is never guaranteed, but we are hoping Elocta will be accessible to patients from 1 July,” he says. ... Compared to normal timelines, the requirements for haemophilia could be quite frustrating, but Neil is sanguine about the need to wait,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics